Softbank Group - Q1 21 Results Reaction: A Slow Shift in Focus

Softbank - No Buyback Means Little Reason to Buy

Softbank Group - The Great Unwinding Has Shifted from the Discount to Underlying Value

Softbank Group - China Has Just Blown a Hole in Vision Fund’s Rapid Listing Theme

Softbank Group - Vision Fund 2’s Late-Private Investments Blur the Lines with Northstar

Softbank Group and Didi Chuxing - Regulatory Pressure on the Rise

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Telco/Internet specialist

Kirk Boodry

Redex Research

Equity Bottom-Up

<p>Nvidia shares are up 61% since it announced the acquisition of ARM.  That is great news for <a href="https://www.smartkarma.com/entities/softbank-group-corp" target="_blank" data-smartkarma-citation="entities:315:1" rel="noopener">Softbank Group (9984 JP)</a> , which has seen the pro rata value of its potential NVDA shares soar $11bn (87% economic stake) with almost half that gain coming in the last three months. That stands in stark contrast to the SBG share price (-37% since 10 May) or the value of key assets like Alibaba (-12%) or Vision Fund (-2%). In fact, the absolute return for SBG shareholders is now better than what Coupang produced whilst the unrealized gains alone are worth more than Vision Fund’s China ADR portfolio. The downside is Softbank could lose that if regulatory approvals stumble and as China is the likely flashpoint for that, recent worries on China exposure could get even worse.</p>

Nvidia shares are up 61% since it announced the acquisition of ARM.  That is great news for Softbank Group (9984 JP) , which has seen the pro rata value of its potential NVDA shares soar $11bn (87% economic stake) with almost half that gain coming in the last three months. That stands in stark contrast to the SBG share price (-37% since 10 May) or the value of key assets like Alibaba (-12%) or Vision Fund (-2%). In fact, the absolute return for SBG shareholders is now better than what Coupang produced whilst the unrealized gains alone are worth more than Vision Fund’s China ADR portfolio. The downside is Softbank could lose that if regulatory approvals stumble and as China is the likely flashpoint for that, recent worries on China exposure could get even worse.

Softbank Group - ARM Optionality and Exposure Are on the Rise